Aditya Birla Sun Life Mutual Fund increased its stake in Ajanta Pharma from 1.10% to 2.21%, acquiring an additional 13,84,420 shares for approximately ₹409.98 Cr at an average price of ₹2,968 apiece.
A manufacturer of specialty pharmaceutical finished dosages, this company develops and markets formulations across therapeutic categories including ophthalmology, gastroenterology, and dermatology for domestic and international markets. With vertically integrated operations spanning development, manufacturing, and marketing, the company has established a significant presence in India's pharmaceutical sector through its robust distribution network and focus on quality production.
Joint venture between Aditya Birla Capital and Sun Life Financial of Canada. Among India's top five AMCs with over Rs 6.5 lakh crore in AUM across 100+ schemes. MD and CEO A. Balasubramanian is one of the most outspoken fund industry voices in India. CIO Mahesh Patil oversees the equity book with a consistent large and multicap tilt.
